7,316 reports of this reaction
6.6% of all NIRMATRELVIR AND RITONAVIR reports
#3 most reported adverse reaction
DYSGEUSIA is the #3 most commonly reported adverse reaction for NIRMATRELVIR AND RITONAVIR, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 7,316 FDA adverse event reports linking NIRMATRELVIR AND RITONAVIR to DYSGEUSIA. This represents approximately 6.6% of all 110,406 adverse event reports for this drug.
NIRMATRELVIR AND RITONAVIR has an overall safety score of 75 out of 100. Patients taking NIRMATRELVIR AND RITONAVIR who experience dysgeusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSGEUSIA is moderately reported among NIRMATRELVIR AND RITONAVIR users, representing a notable but not dominant share of adverse events.
In addition to dysgeusia, the following adverse reactions have been reported for NIRMATRELVIR AND RITONAVIR:
The following drugs have also been linked to dysgeusia in FDA adverse event reports:
DYSGEUSIA has been reported as an adverse event in 7,316 FDA reports for NIRMATRELVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSGEUSIA accounts for approximately 6.6% of all adverse event reports for NIRMATRELVIR AND RITONAVIR, making it one of the most commonly reported side effect.
If you experience dysgeusia while taking NIRMATRELVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.